HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Stephenson, I. Articles by Nicholson, K.G. Search for Related Content PubMed PubMed Citation Articles by Stephenson, I. Articles by Nicholson, K.G.

Influenza: vaccination and treatment

Dept of Infection and Tropical Medicine, Leicester Royal Infirmary, Leicester, UK

CORRESPONDENCE: I. Stephenson, Dept of Infection and Tropical Medicine, Leicester Royal Infirmary, Leicester, LE1 5WW, UK. Fax: 44 1162585067

Keywords: antiviral drugs, influenza, neuraminidase, vaccination

Received: September 25, 2000
Accepted October 3, 2000

Abstract

Few conditions exert such an enormous toll of absenteeism, suffering, medical consultations, hospitalization, death and economic loss as influenza. Patients at high risk of complications and mortality include the elderly and those with pre-existing cardiopulmonary disease.

The outbreak in 1997 in Hong Kong, of avian H5N1 influenza in man, which resulted in six deaths among 18 hospitalized cases, and the recent isolation of H9N2 viruses from two children in Hong Kong, are reminders that preparation must be made for the next pandemic. Since the 1970s, efforts to control influenza have mostly focussed on the split product and surface antigen vaccines. These vaccines are of proven efficacy in healthy adults and are effective in elderly people with and without medical conditions putting them at high risk of complications and death following influenza infection.

However, vaccine coverage is patchy and often low, and outbreaks of influenza are not uncommon in well-immunized residents of nursing homes. New vaccines and methods of vaccine delivery are being developed in attempts to overcome the limitations of existing vaccines.

The antiviral drugs amantadine and rimantadine were developed in the 1960s, but have not been used widely due to their spectrum of activity, rapid emergence of resistance, and adverse effects associated with amantadine. The site of enzyme activity of the influenza neuraminidase is highly conserved between types, subtypes and strains of influenza and has emerged as the target of an exciting new class of antiviral agents that are effective both prophylactically and as therapy.

This article has been cited by other articles:

				H. Zhang Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza J. Antimicrob. Chemother., January 31, 2008; (2008) dkn026v1. [Abstract] [Full Text] [PDF]

				J. J. Schentag, G. Hill, T. Chu, and C. R. Rayner Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects J. Clin. Pharmacol., June 1, 2007; 47(6): 689 - 696. [Abstract] [Full Text] [PDF]

				B. T. Hu, X. Yu, T. R. Jones, C. Kirch, S. Harris, S. W. Hildreth, D. V. Madore, and S. A. Quataert Approach to Validating an Opsonophagocytic Assay for Streptococcus pneumoniae Clin. Vaccine Immunol., February 1, 2005; 12(2): 287 - 295. [Abstract] [Full Text] [PDF]